GB2545898B - Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides - Google Patents

Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides Download PDF

Info

Publication number
GB2545898B
GB2545898B GB1522548.5A GB201522548A GB2545898B GB 2545898 B GB2545898 B GB 2545898B GB 201522548 A GB201522548 A GB 201522548A GB 2545898 B GB2545898 B GB 2545898B
Authority
GB
United Kingdom
Prior art keywords
dccpm
peptide
stap
bac
pmo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1522548.5A
Other languages
English (en)
Other versions
GB201522548D0 (en
GB2545898A (en
Inventor
Foster Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutura Therapeutics Ltd
Original Assignee
Sutura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutura Therapeutics Ltd filed Critical Sutura Therapeutics Ltd
Priority to GB1912318.1A priority Critical patent/GB2574525B/en
Priority to GB1522548.5A priority patent/GB2545898B/en
Publication of GB201522548D0 publication Critical patent/GB201522548D0/en
Priority to KR1020187020172A priority patent/KR20180091920A/ko
Priority to PCT/GB2016/054028 priority patent/WO2017109494A1/en
Priority to CN201680073127.3A priority patent/CN108472385A/zh
Priority to US16/061,548 priority patent/US11541124B2/en
Priority to AU2016375869A priority patent/AU2016375869B2/en
Priority to EP16822244.6A priority patent/EP3393520A1/en
Priority to BR112018012641A priority patent/BR112018012641A2/pt
Priority to JP2018550872A priority patent/JP2019508481A/ja
Priority to CA3007910A priority patent/CA3007910A1/en
Publication of GB2545898A publication Critical patent/GB2545898A/en
Application granted granted Critical
Publication of GB2545898B publication Critical patent/GB2545898B/en
Priority to US18/088,933 priority patent/US11944688B2/en
Priority to JP2023014917A priority patent/JP2023055874A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
GB1522548.5A 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides Expired - Fee Related GB2545898B (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GB1912318.1A GB2574525B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB1522548.5A GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
JP2018550872A JP2019508481A (ja) 2015-12-21 2016-12-21 ステープルまたはステッチペプチドに複合された生物活性化合物
KR1020187020172A KR20180091920A (ko) 2015-12-21 2016-12-21 스테이플화 또는 스티치화 펩타이드에 컨쥬게이션된 생물학적 활성 화합물
CN201680073127.3A CN108472385A (zh) 2015-12-21 2016-12-21 与钉合或拼接肽缀合的生物活性化合物
US16/061,548 US11541124B2 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide
AU2016375869A AU2016375869B2 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide
EP16822244.6A EP3393520A1 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide
BR112018012641A BR112018012641A2 (pt) 2015-12-21 2016-12-21 molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição.
PCT/GB2016/054028 WO2017109494A1 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide
CA3007910A CA3007910A1 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide
US18/088,933 US11944688B2 (en) 2015-12-21 2022-12-27 Biologically active compounds
JP2023014917A JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1522548.5A GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides

Publications (3)

Publication Number Publication Date
GB201522548D0 GB201522548D0 (en) 2016-02-03
GB2545898A GB2545898A (en) 2017-07-05
GB2545898B true GB2545898B (en) 2019-10-09

Family

ID=55311362

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1522548.5A Expired - Fee Related GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides

Country Status (10)

Country Link
US (2) US11541124B2 (enExample)
EP (1) EP3393520A1 (enExample)
JP (2) JP2019508481A (enExample)
KR (1) KR20180091920A (enExample)
CN (1) CN108472385A (enExample)
AU (1) AU2016375869B2 (enExample)
BR (1) BR112018012641A2 (enExample)
CA (1) CA3007910A1 (enExample)
GB (1) GB2545898B (enExample)
WO (1) WO2017109494A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
KR20240172236A (ko) 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN111447941B (zh) 2017-10-27 2023-10-31 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
EP3749678A1 (en) 2018-02-07 2020-12-16 Dana Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
US11459304B2 (en) 2018-08-31 2022-10-04 Massachusetts Institute Of Technology Ionizable lipidoids and their uses
JP7727551B2 (ja) * 2019-04-18 2025-08-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 構造的に安定化されたペプチドによるユビキチンおよびユビキチン様ｅ１活性化酵素の選択的標的化
KR102544364B1 (ko) * 2019-06-17 2023-06-19 주식회사 안단테에프엠 Romo1 유래 항균 펩타이드 및 그 변이체
KR102521182B1 (ko) * 2020-11-06 2023-04-12 서울대학교산학협력단 결핵균 독소-항독소 시스템을 표적으로 하는 항균 스테이플 펩타이드 및 이의 용도
WO2024069229A2 (en) 2022-08-03 2024-04-04 Sutura Therapeutics Ltd Biologically active compounds
WO2025027389A1 (en) 2023-08-03 2025-02-06 Sutura Therapeutics Limited Biologically active compounds comprising a stapled or stitched peptide

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003849A1 (en) * 1987-10-28 1989-05-05 Howard Florey Institute Of Experimental Physiology Oligonucleotide-polyamide conjugates
WO2009054725A2 (en) * 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2010123369A1 (en) * 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
WO2011131693A2 (en) * 2010-04-19 2011-10-27 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
WO2014053622A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014064258A1 (en) * 2012-10-26 2014-05-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533170A (ja) 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子
WO2009149214A2 (en) 2008-06-03 2009-12-10 Aileron Therapeutics, Inc. Compositions and methods for enhancing cellular transport of biomolecules
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011111874A1 (ja) 2010-03-11 2011-09-15 独立行政法人理化学研究所 細胞膜透過性ダンベル型rnaおよびその製造方法
AU2011367230B2 (en) 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013030569A2 (en) 2011-08-30 2013-03-07 Michael John Gait Peptides
CN103121959B (zh) 2011-11-21 2016-09-21 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 化合物和核酸复合分子与核酸复合物及其制备方法和应用
CN103626850B (zh) 2013-04-03 2015-08-26 安徽省新星药物开发有限责任公司 具有细胞穿透功能的多肽及其在药物递送中的用途
KR102644053B1 (ko) 2015-05-19 2024-03-06 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트
HK1257747A1 (zh) 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB2563875B (en) 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003849A1 (en) * 1987-10-28 1989-05-05 Howard Florey Institute Of Experimental Physiology Oligonucleotide-polyamide conjugates
WO2009054725A2 (en) * 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2010123369A1 (en) * 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
WO2011131693A2 (en) * 2010-04-19 2011-10-27 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
WO2014053622A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014064258A1 (en) * 2012-10-26 2014-05-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biopolymers, Vol 73, 2004, IA Kozlov et al, "Efficient strategies for the conjugation of oligonucleotides to antibodies enabling highly sensitive protein detection", 621-630 *
JACS, Vol 136, 2014, GJ Hilinski et al, "Stitched a-helical peptides via bis ring-closing metathesis", 12314- 12322 *

Also Published As

Publication number Publication date
CA3007910A1 (en) 2017-06-29
AU2016375869B2 (en) 2023-07-13
AU2016375869A1 (en) 2018-08-09
CN108472385A (zh) 2018-08-31
US20200353092A1 (en) 2020-11-12
US20230158166A1 (en) 2023-05-25
US11541124B2 (en) 2023-01-03
US11944688B2 (en) 2024-04-02
JP2019508481A (ja) 2019-03-28
GB201522548D0 (en) 2016-02-03
JP2023055874A (ja) 2023-04-18
BR112018012641A2 (pt) 2018-12-04
GB2545898A (en) 2017-07-05
WO2017109494A1 (en) 2017-06-29
KR20180091920A (ko) 2018-08-16
EP3393520A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
US11944688B2 (en) Biologically active compounds
JP2019508481A5 (enExample)
CA2846218C (en) Cell-penetrating peptides having a central hydrophobic domain
US8575305B2 (en) Cell penetrating peptides
EP4058032A1 (en) Compositions for delivery of antisense compounds
US20220062431A1 (en) Compounds comprising stapled or stitched peptides for improved drug delivery
JP2020525462A5 (ja) 改善された薬物送達のためのステープルされた又はステッチされたペプチドを含む化合物
AU2022354260A1 (en) Conjugated oligonucleotides and uses thereof
JP2023545546A (ja) 遺伝子発現調節のための非アニオン性ポリヌクレオチド類似体のペプチドに基づく導入
WO2024069229A2 (en) Biologically active compounds
GB2574525A (en) Improvements in drug delivery
GB2580569A (en) Improvements in drug delivery
HK1194389B (en) Cell-penetrating peptides having a central hydrophobic domain
HK1194389A (en) Cell-penetrating peptides having a central hydrophobic domain

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20241221